Multisystemic inflammatory syndrome related to COVID-19, with latent tuberculosis in bone marrow, and satisfactory response to tocilizumab, in a 7-year-old boy

• Published in: Reumatismo 2022-02, Vol.73 (4)
• Main Authors: Morel, Z, Suarez, R, Avalos, E, Velázquez, S, Martínez, F, Lezcano, V, Astigarraga, N, Ghezzi, C, Brizuela, S, Samudio, G
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal, Humanized; Bone Marrow; Child; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - drug therapy; Humans; Latent Tuberculosis - complications; Latent Tuberculosis - diagnosis; Latent Tuberculosis - drug therapy; Male; Multisystem inflammatory syndrome in children; Multisystemic inflammatory syndrome in children; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Tuberculosis
• ISSN: 0048-7449; 2240-2683
• DOI: 10.4081/reumatismo.2021.1448

Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C) is a new acute-onset systemic inflammatory disease, which mainly affects children. Latent tuberculosis infection (LTBI) is characterized by the presence of immune sensitization to Mycobacterium tuberculosis (MTB) in the absence of any clinical or radiological evidence of active disease. We present a child with MIS-C related to COVID-19, with latent TB in the bone marrow, and satisfactory response to tocilizumab. It is important to pay attention in the investigation of TB cases in countries with a high prevalence of tuberculosis, especially when opting for immunusuppression.